Chong Kun Dang Holdings Corp. (KRX:001630)
47,900
+200 (0.42%)
At close: Sep 5, 2025
Chong Kun Dang Holdings Revenue
Chong Kun Dang Holdings had revenue of 242.18B KRW in the quarter ending June 30, 2025, a decrease of -2.52%. This brings the company's revenue in the last twelve months to 948.12B, up 0.22% year-over-year. In the year 2024, Chong Kun Dang Holdings had annual revenue of 957.75B with 8.86% growth.
Revenue (ttm)
948.12B
Revenue Growth
+0.22%
P/S Ratio
0.24
Revenue / Employee
25.62B
Employees
37
Market Cap
228.03B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 957.75B | 77.97B | 8.86% |
Dec 31, 2023 | 879.78B | -29.18B | -3.21% |
Dec 31, 2022 | 908.96B | -17.01B | -1.84% |
Dec 31, 2021 | 925.98B | 67.86B | 7.91% |
Dec 31, 2020 | 858.12B | 137.47B | 19.08% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 5,031.69B |
Celltrion | 3,748.95B |
ALTEOGEN | 158.06B |
Yuhan | 2,165.44B |
SK Biopharmaceuticals | 620.28B |
Peptron | 5.18B |
PharmaResearch | 449.81B |
LigaChem Biosciences | 148.28B |